NASDAQ:AMRN - Amarin Stock Price, Price Target & More

$2.68 -0.11 (-3.94 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$2.79
Today's Range$2.66 - $2.85
52-Week Range$2.66 - $4.60
Volume6.26 million shs
Average Volume2.23 million shs
Market Capitalization$824.34 million
P/E Ratio-10.88
Dividend YieldN/A
Beta0.72

About Amarin (NASDAQ:AMRN)

Amarin logoAmarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its product principally to wholesalers and specialty pharmacy providers through direct sales force. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AMRN
CUSIPN/A
Phone353-1669-9020

Debt

Debt-to-Equity Ratio-1.12%
Current Ratio1.41%
Quick Ratio1.13%

Price-To-Earnings

Trailing P/E Ratio-10.88
Forward P/E Ratio-8.12
P/E GrowthN/A

Sales & Book Value

Annual Sales$181.10 million
Price / Sales4.33
Cash FlowN/A
Price / CashN/A
Book Value($0.33) per share
Price / Book-8.12

Profitability

EPS (Most Recent Fiscal Year)($0.25)
Net Income$-67,860,000.00
Net Margins-37.47%
Return on EquityN/A
Return on Assets-40.30%

Miscellaneous

Employees241
Outstanding Shares292,320,000

How to Become a New Pot Stock Millionaire

Amarin (NASDAQ:AMRN) Frequently Asked Questions

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

How were Amarin's earnings last quarter?

Amarin Co. (NASDAQ:AMRN) posted its quarterly earnings data on Tuesday, February, 27th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.03. The biopharmaceutical company had revenue of $53.87 million for the quarter, compared to analysts' expectations of $52.73 million. Amarin's revenue was up 39.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.10) EPS. View Amarin's Earnings History.

When is Amarin's next earnings date?

Amarin is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Amarin.

What price target have analysts set for AMRN?

3 equities research analysts have issued 1 year price objectives for Amarin's stock. Their predictions range from $7.00 to $10.00. On average, they expect Amarin's share price to reach $9.00 in the next year. View Analyst Ratings for Amarin.

What are Wall Street analysts saying about Amarin stock?

Here are some recent quotes from research analysts about Amarin stock:
  • 1. Cantor Fitzgerald analysts commented, "Amarin announced the presentation of two posters at the National Kidney Foundation 2018 Spring Clinical Meetings in Austin, TX. These data, along with what we expect to be positive results from Amarin’s REDUCE-IT study by 3Q18, support our investment thesis for the stock. This is because a large portion of the male and female patients enrolled in this outcomes study are anticipated to also be diagnosed with type 2 diabetes." (4/12/2018)
  • 2. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (3/2/2018)

Who are some of Amarin's key competitors?

Who are Amarin's key executives?

Amarin's management team includes the folowing people:
  • Mr. John F. Thero, Chief Exec. Officer, Pres and Director (Age 57)
  • Mr. Michael W. Kalb CPA, Chief Financial Officer and Sr. VP (Age 47)
  • Dr. Steven B. Ketchum, Chief Scientific Officer, Pres of R&D and Sr. VP (Age 53)
  • Mr. Joseph T. Kennedy J.D., Chief Compliance Officer, Exec. VP of Strategic Initiatives, Gen. Counsel and Sec. (Age 50)
  • Mr. Frederick W. Ahlholm CPA, Chief Accounting Officer and VP of Fin. & Admin. (Age 52)

Has Amarin been receiving favorable news coverage?

News stories about AMRN stock have trended somewhat positive this week, according to Accern. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amarin earned a news sentiment score of 0.14 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 45.49 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $2.68.

How big of a company is Amarin?

Amarin has a market capitalization of $824.34 million and generates $181.10 million in revenue each year. The biopharmaceutical company earns $-67,860,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Amarin employs 241 workers across the globe.

How can I contact Amarin?

Amarin's mailing address is 2 Pembroke House Upper Pembroke Street 28-32, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]


MarketBeat Community Rating for Amarin (AMRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  454 (Vote Outperform)
Underperform Votes:  267 (Vote Underperform)
Total Votes:  721
MarketBeat's community ratings are surveys of what our community members think about Amarin and other stocks. Vote "Outperform" if you believe AMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amarin (NASDAQ:AMRN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Amarin in the last 12 months. Their average twelve-month price target is $9.00, suggesting that the stock has a possible upside of 235.82%. The high price target for AMRN is $10.00 and the low price target for AMRN is $7.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.00$9.00$9.00$9.00
Price Target Upside: 235.82% upside150.00% upside122.77% upside163.93% upside

Amarin (NASDAQ:AMRN) Consensus Price Target History

Price Target History for Amarin (NASDAQ:AMRN)

Amarin (NASDAQ:AMRN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/12/2018Cantor FitzgeraldReiterated RatingBuy$10.00LowView Rating Details
3/1/2018HC WainwrightReiterated RatingBuyLowView Rating Details
10/11/2017Jefferies GroupReiterated RatingBuyN/AView Rating Details
10/19/2016CitigroupInitiated CoverageBuy$5.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Amarin (NASDAQ:AMRN) Earnings History and Estimates Chart

Earnings by Quarter for Amarin (NASDAQ:AMRN)

Amarin (NASDAQ:AMRN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.33)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.09)($0.05)($0.07)
Q2 20182($0.09)($0.06)($0.08)
Q3 20182($0.08)($0.05)($0.07)
Q4 20182($0.15)($0.09)($0.12)

Amarin (NASDAQ AMRN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018        
2/27/2018n/a($0.05)($0.08)$52.73 million$53.87 millionViewN/AView Earnings Details
11/1/2017Q3 2017($0.05)($0.04)$45.85 million$47.10 millionViewN/AView Earnings Details
8/2/20176/30/2017($0.06)($0.05)$40.35 million$44.95 millionViewListenView Earnings Details
5/4/20173/31/2017($0.07)($0.08)$37.85 million$34.60 millionViewListenView Earnings Details
2/28/201712/31/2016($0.09)($0.05)$36.13 million$38.40 millionViewListenView Earnings Details
11/3/2016Q316($0.10)($0.08)$32.03 million$32.40 millionViewN/AView Earnings Details
8/4/2016Q216($0.13)($0.07)$29.97 million$32.82 millionViewN/AView Earnings Details
5/5/2016Q116($0.11)($0.14)$26.77 million$25.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.08)($0.12)$23.62 million$26.40 millionViewListenView Earnings Details
11/4/2015Q315($0.12)($0.18)$21.93 million$21.30 millionViewN/AView Earnings Details
8/6/2015Q2($0.12)($0.15)$19.10 million$17.70 millionViewN/AView Earnings Details
5/8/2015Q115($0.11)($0.18)$21.86 million$15.60 millionViewN/AView Earnings Details
3/3/2015Q414($0.13)($0.11)$17.40 million$16.50 millionViewN/AView Earnings Details
11/6/2014Q314($0.14)($0.18)$14.87 million$14.15 millionViewN/AView Earnings Details
8/7/2014Q214($0.15)($0.14)$12.86 million$12.60 millionViewN/AView Earnings Details
5/9/2014Q114($0.18)($0.17)$11.65 million$11.00 millionViewN/AView Earnings Details
2/27/2014Q413($0.23)($0.26)$11.17 million$10.10 millionViewN/AView Earnings Details
11/7/2013($0.32)($0.25)$10.25 million$8.40 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.38)($0.26)$5.50 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.39)($0.41)$5.21 million$2.34 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.28)($0.28)ViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.26)ViewN/AView Earnings Details
8/8/2012Q2 2012($0.15)($0.24)ViewN/AView Earnings Details
5/8/2012Q1 2012($0.09)($0.15)ViewN/AView Earnings Details
2/29/2012Q4 2011($0.08)($0.08)ViewN/AView Earnings Details
11/7/2011Q3 2011($0.13)($0.10)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.12)$2.51ViewN/AView Earnings Details
5/10/2011Q1 2011($0.08)($0.05)ViewN/AView Earnings Details
3/16/2011Q4 2010($0.08)$0.17ViewN/AView Earnings Details
9/25/2008Q2 2008$0.01ViewN/AView Earnings Details
5/19/2008Q4 2007($0.61)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Amarin (NASDAQ:AMRN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Amarin (NASDAQ AMRN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.72%
Institutional Ownership Percentage: 38.18%
Insider Trading History for Amarin (NASDAQ:AMRN)
Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Amarin (NASDAQ AMRN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/3/2018Joseph T KennedyGeneral CounselSell26,942$2.90$78,131.80View SEC Filing  
1/31/2018Joseph T KennedyGeneral CounselSell44,857$3.73$167,316.61View SEC Filing  
1/23/2018Steven B KetchumInsiderSell135,205$4.41$596,254.05View SEC Filing  
1/17/2018Joseph T KennedyGeneral CounselSell51,106$4.10$209,534.60View SEC Filing  
1/11/2018Steven B KetchumInsiderSell2,612$4.40$11,492.80View SEC Filing  
1/5/2018Steven B KetchumInsiderSell64,683$4.40$284,605.20View SEC Filing  
1/2/2018Steven B KetchumInsiderSell128,257$4.25$545,092.25View SEC Filing  
11/30/2017John F TheroInsiderBuy10,000$3.24$32,400.00View SEC Filing  
10/5/2017Steven B KetchumInsiderSell63,479$3.48$220,906.92View SEC Filing  
7/3/2017Joseph T. KennedyGeneral CounselSell307,911$4.00$1,231,644.00View SEC Filing  
2/1/2016John F TheroCEOBuy25,000$1.37$34,250.00661,743View SEC Filing  
8/11/2015John F TheroCEOBuy20,000$2.35$47,000.00View SEC Filing  
11/12/2014John F TheroInsiderBuy50,000$0.83$41,500.00View SEC Filing  
11/11/2014Michael James FarrellInsiderBuy5,500$0.84$4,620.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amarin (NASDAQ AMRN) News Headlines

Source:
DateHeadline
$43.35 Million in Sales Expected for Amarin Co. (AMRN) This Quarter$43.35 Million in Sales Expected for Amarin Co. (AMRN) This Quarter
www.americanbankingnews.com - April 21 at 5:34 AM
-$0.07 Earnings Per Share Expected for Amarin Co. (AMRN) This Quarter-$0.07 Earnings Per Share Expected for Amarin Co. (AMRN) This Quarter
www.americanbankingnews.com - April 19 at 3:24 AM
Amarin (AMRN) Stock Rating Reaffirmed by Jefferies GroupAmarin (AMRN) Stock Rating Reaffirmed by Jefferies Group
www.americanbankingnews.com - April 13 at 11:43 PM
Amarins (AMRN) Buy Rating Reiterated at HC WainwrightAmarin's (AMRN) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - April 13 at 12:59 PM
Amarin Corp. (AMRN) Reports Vascepa (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and ...Amarin Corp. (AMRN) Reports Vascepa (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and ...
www.streetinsider.com - April 13 at 8:55 AM
New Research: Key Drivers of Growth for Amarin, Korea Electric Power, Star Bulk Carriers, 1-800 FLOWERS.COM ...New Research: Key Drivers of Growth for Amarin, Korea Electric Power, Star Bulk Carriers, 1-800 FLOWERS.COM ...
globenewswire.com - April 13 at 8:55 AM
Moving Average Crossover Alert: Amarin (AMRN) April 12, 2018Moving Average Crossover Alert: Amarin (AMRN) April 12, 2018
www.zacks.com - April 12 at 5:11 PM
Moving Average Crossover Alert: Amarin (AMRN)Moving Average Crossover Alert: Amarin (AMRN)
finance.yahoo.com - April 12 at 5:11 PM
Amarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific SessionsAmarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions
finance.yahoo.com - April 12 at 5:11 PM
HC Wainwright Reaffirms "Buy" Rating for Amarin (AMRN)HC Wainwright Reaffirms "Buy" Rating for Amarin (AMRN)
www.americanbankingnews.com - April 12 at 3:58 PM
Cantor Fitzgerald Reiterates "$10.00" Price Target for Amarin (AMRN)Cantor Fitzgerald Reiterates "$10.00" Price Target for Amarin (AMRN)
www.americanbankingnews.com - April 12 at 11:39 AM
Amarin presents posters in statin-treated patients with reduced kidney function and diabetes or elevated hsCRP with ...Amarin presents posters in statin-treated patients with reduced kidney function and diabetes or elevated hsCRP with ...
seekingalpha.com - April 12 at 9:20 AM
Amarin: Waiting For REDUCE-IT ResultsAmarin: Waiting For REDUCE-IT Results
seekingalpha.com - April 11 at 9:07 AM
Amarin (AMRN) Downgraded by ValuEngine to SellAmarin (AMRN) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - April 10 at 7:51 PM
Amarin (AMRN) Upgraded to "Hold" by ValuEngineAmarin (AMRN) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - April 9 at 6:24 PM
FY2020 EPS Estimates for Amarin Co. (AMRN) Reduced by Jefferies GroupFY2020 EPS Estimates for Amarin Co. (AMRN) Reduced by Jefferies Group
www.americanbankingnews.com - April 9 at 2:30 AM
Wired News – Amarin’s REDUCE-IT Study Reached 100% Mark for Estimated Onset of Targeted Primary MACEWired News – Amarin’s REDUCE-IT Study Reached 100% Mark for Estimated Onset of Targeted Primary MACE
finance.yahoo.com - April 6 at 8:55 AM
Boom-or-Bust News Is On Tap Soon for AmarinBoom-or-Bust News Is On Tap Soon for Amarin
finance.yahoo.com - April 5 at 10:46 AM
Joseph T. Kennedy Sells 26,942 Shares of Amarin Co. (AMRN) StockJoseph T. Kennedy Sells 26,942 Shares of Amarin Co. (AMRN) Stock
www.americanbankingnews.com - April 4 at 1:28 PM
Amarin (AMRN) Given a $10.00 Price Target by Cantor Fitzgerald AnalystsAmarin (AMRN) Given a $10.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - April 4 at 10:27 AM
Amarin updates Q1 revenue guidance and updates on REDUCE-IT study progress and Vascepa promotion initiativesAmarin updates Q1 revenue guidance and updates on REDUCE-IT study progress and Vascepa promotion initiatives
seekingalpha.com - April 4 at 8:47 AM
Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT ...Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT ...
globenewswire.com - April 4 at 8:47 AM
Amarin Corp. (AMRN) Lowers 1Q18 Revenue Guidance to Approx. $43M (from $45M-$48M); Reiterates FY18 ...Amarin Corp. (AMRN) Lowers 1Q18 Revenue Guidance to Approx. $43M (from $45M-$48M); Reiterates FY18 ...
www.streetinsider.com - April 4 at 8:47 AM
BRIEF-Amarins says 100 pct Mark reached on REDUCE-IT Cardiovascular Outcomes Study for Estimated Onset of ...BRIEF-Amarin's says 100 pct Mark reached on REDUCE-IT Cardiovascular Outcomes Study for Estimated Onset of ...
www.reuters.com - April 4 at 8:47 AM
Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa® Promotion InitiativesAmarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa® Promotion Initiatives
finance.yahoo.com - April 4 at 8:47 AM
$45.87 Million in Sales Expected for Amarin Co. (AMRN) This Quarter$45.87 Million in Sales Expected for Amarin Co. (AMRN) This Quarter
www.americanbankingnews.com - April 4 at 4:54 AM
Amarin (AMRN) Given a $10.00 Price Target at Cantor FitzgeraldAmarin (AMRN) Given a $10.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - April 2 at 2:04 PM
7 Stocks for the Biotech Takeover Wave7 Stocks for the Biotech Takeover Wave
finance.yahoo.com - April 2 at 9:09 AM
-$0.06 EPS Expected for Amarin Co. (AMRN) This Quarter-$0.06 EPS Expected for Amarin Co. (AMRN) This Quarter
www.americanbankingnews.com - April 2 at 3:20 AM
Amarin (AMRN) Stock Rating Reaffirmed by HC WainwrightAmarin (AMRN) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - April 1 at 11:24 PM
Amarin Co. (AMRN) Given Average Rating of "Hold" by BrokeragesAmarin Co. (AMRN) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 1 at 1:36 AM
Edited Transcript of AMRN earnings conference call or presentation 27-Feb-18 12:30pm GMTEdited Transcript of AMRN earnings conference call or presentation 27-Feb-18 12:30pm GMT
finance.yahoo.com - March 31 at 8:41 AM
Amarin to Present at the HC Wainwright Annual Global Life Sciences ConferenceAmarin to Present at the HC Wainwright Annual Global Life Sciences Conference
globenewswire.com - March 28 at 5:00 PM
Amarin to Present at the H.C. Wainwright Annual Global Life Sciences ConferenceAmarin to Present at the H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - March 28 at 5:00 PM
Amarin Commemorates National Triglycerides Day on March 28Amarin Commemorates National Triglycerides Day on March 28
finance.yahoo.com - March 27 at 4:55 PM
Amarin (AMRN) Rating Lowered to Hold at BidaskClubAmarin (AMRN) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - March 27 at 4:00 PM
Amarin (AMRN) Downgraded by BidaskClub to SellAmarin (AMRN) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - March 26 at 9:13 AM
7 Biotech Movers To Watch Today: Prothena, Proteostasis, Global Blood Therapeutics And More - Benzinga7 Biotech Movers To Watch Today: Prothena, Proteostasis, Global Blood Therapeutics And More - Benzinga
www.benzinga.com - March 21 at 5:17 PM
Amarin Announces First Middle East Approval for Vascepa® - GlobeNewswire (press release)Amarin Announces First Middle East Approval for Vascepa® - GlobeNewswire (press release)
globenewswire.com - March 21 at 9:36 AM
Amarin Announces First Middle East Approval for Vascepa®Amarin Announces First Middle East Approval for Vascepa®
finance.yahoo.com - March 21 at 9:36 AM
Amarin (AMRN) Rating Increased to Sell at BidaskClubAmarin (AMRN) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - March 17 at 7:16 PM
New Research Coverage Highlights Amarin, Corbus Pharmaceuticals, Green Brick Partners, Immutep, Texas Capital Bancshares, and G1 THERAPEUTICS — Consolidated Revenues, Company Growth, and Expectations for 2018New Research Coverage Highlights Amarin, Corbus Pharmaceuticals, Green Brick Partners, Immutep, Texas Capital Bancshares, and G1 THERAPEUTICS — Consolidated Revenues, Company Growth, and Expectations for 2018
finance.yahoo.com - March 16 at 8:51 AM
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein (hsCRP)Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein (hsCRP)
finance.yahoo.com - March 12 at 6:13 PM
Real-World Data Supports Association Between Elevated Triglyceride Levels and Increased Cardiovascular Events and Healthcare CostsReal-World Data Supports Association Between Elevated Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs
finance.yahoo.com - March 12 at 6:13 PM
Cantor Fitzgerald Analysts Give Amarin (AMRN) a $10.00 Price TargetCantor Fitzgerald Analysts Give Amarin (AMRN) a $10.00 Price Target
www.americanbankingnews.com - March 12 at 2:25 PM
Amarin Co. plc (AMRN) Sees Significant Growth in Short InterestAmarin Co. plc (AMRN) Sees Significant Growth in Short Interest
www.americanbankingnews.com - March 11 at 1:58 AM
Cramer's lightning round: I screwed up on Apache and won'...Cramer's lightning round: I screwed up on Apache and won'...
finance.yahoo.com - March 10 at 8:44 AM
Cramers lightning round: I screwed up on Apache and wont stop you from sellingCramer's lightning round: I screwed up on Apache and won't stop you from selling
finance.yahoo.com - March 10 at 8:44 AM
Amarin Announces Closing of Underwriters Purchase of Additional Shares - GlobeNewswire (press release)Amarin Announces Closing of Underwriter's Purchase of Additional Shares - GlobeNewswire (press release)
globenewswire.com - March 7 at 8:49 AM
Implied Volatility Surging for Amarin (AMRN) Stock Options - NasdaqImplied Volatility Surging for Amarin (AMRN) Stock Options - Nasdaq
www.nasdaq.com - March 7 at 8:49 AM

SEC Filings

Amarin (NASDAQ:AMRN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amarin (NASDAQ:AMRN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amarin (NASDAQ AMRN) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.